Skin Elements Limited (AU:SKN)
ASX:SKN
Top Page
Skin Elements Limited
(Sydney:SKN)
Select Model
Select Model
Rating:45Neutral
Price Target:
AU$0.01
▲(266.67% Upside)
Action:UpgradedDate:12/30/25
The score is primarily constrained by weak financial performance, especially persistent heavy losses on a small/volatile revenue base and negative shareholder equity. Offsetting this, FY2025 showed a notable turnaround to positive operating and free cash flow, but sustainability is uncertain. Technical and valuation inputs are largely unavailable, so they contribute mostly neutral impact.
Positive Factors
Positive Cash Flow
The shift to positive cash flow in FY2025 indicates improved operational efficiency and potential for sustainable financial health if maintained.
Negative Factors
Negative Shareholder Equity
Negative equity indicates financial instability, limiting the company's ability to absorb losses and invest in growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive Cash Flow
The shift to positive cash flow in FY2025 indicates improved operational efficiency and potential for sustainable financial health if maintained.
Read all positive factors
Skin Elements Limited (SKN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$12.00M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)2.65
Revenue Growth12.92%
EPS Growth34.21%
CountryAU
EmployeesN/A
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,025,214,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.22
Price to Sales (P/S)5.02
P/FCF Ratio10.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Skin Elements Limited Business Overview & Revenue Model
Company Description
Skin Elements Limited, a natural skin care company, develops, manufactures, distributes, and retails natural, organic, health, and wellness products in Australia. The company offers SuprCuvr, a disinfectant spray; Soléo Organics sunscreen; Papaya ...
How the Company Makes Money
Skin Elements Limited generates revenue primarily through the sale of its natural skincare and sanitizing products. The company's revenue streams include direct sales via online platforms, partnerships with retail distributors, and wholesale agree...
Skin Elements Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
44
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 340.90K | 469.96K | 416.20K | 194.13K | 1.41M | 288.74K |
| Gross Profit | 279.93K | 406.29K | 361.87K | -204.55K | 742.98K | -213.47K |
| EBITDA | -1.40M | -1.63M | -2.08M | -12.08M | -2.15M | -3.54M |
| Net Income | -4.53M | -1.73M | -2.16M | -11.42M | -1.58M | -3.04M |
Balance Sheet | ||||||
| Total Assets | 2.01M | 720.21K | 1.44M | 1.69M | 11.10M | 11.03M |
| Cash, Cash Equivalents and Short-Term Investments | 1.73M | 59.65K | 115.07K | 358.43K | 748.05K | 287.63K |
| Total Debt | 5.09K | 444.39K | 731.73K | 17.75K | 24.53K | 30.99K |
| Total Liabilities | 429.34K | 2.66M | 3.08M | 1.08M | 1.05M | 1.42M |
| Stockholders Equity | 1.58M | -1.94M | -1.63M | 604.80K | 10.05M | 9.60M |
Cash Flow | ||||||
| Free Cash Flow | -249.21K | 233.85K | -279.38K | -1.84M | -1.50M | -2.74M |
| Operating Cash Flow | -1.35M | 233.85K | -279.38K | -1.84M | -1.50M | -2.70M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -36.41K |
| Financing Cash Flow | 3.02M | -289.27K | 36.02K | 1.45M | 1.96M | 2.82M |
Skin Elements Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$28.35M | 21.25 | 14.06% | 1.54% | 6.89% | 607.27% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | AU$12.00M | -0.26 | 2542.90% | ― | 12.92% | 34.21% | |
44 Neutral | AU$20.31M | -7.05 | -108.90% | ― | 17.41% | 67.94% | |
44 Neutral | AU$1.94M | -0.12 | -168.40% | ― | 24.70% | -312.00% | |
42 Neutral | AU$5.66M | -0.01 | 226.76% | ― | -21.84% | 79.99% |
* Consumer Defensive Sector Average
AU:SKN
Skin Elements Limited
―
―
―
AU:ZNO
Zoono Group Limited
0.05
0.02
78.57%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
-0.01
-43.33%
AU:S66
Star Combo Pharma Ltd.
0.21
0.05
31.25%
AU:TFL
TasFoods Limited
―
―
―
Skin Elements Limited Corporate Events
Skin Elements Expands Share Capital Through Lead Manager Allotment and Option Conversion
Dec 24, 2025
Skin Elements Limited has expanded its share capital through the allotment of 75 million fully paid ordinary shares to a lead manager and the issue of a further 125 million shares upon conversion of unquoted options exercisable at $0.006, ahead of...
Skin Elements Director Peter Malone Restructures Indirect Shareholdings
Dec 24, 2025
Skin Elements Limited has disclosed changes in the indirect equity interests held by director Peter Malone through his associated entities. The notice details the conversion of 119,025,000 options into ordinary shares via Empire Services (AUST) Pt...
Skin Elements Seeks ASX Quotation for 125 Million New Shares
Dec 24, 2025
Skin Elements Limited has applied to the ASX for quotation of 125 million new fully paid ordinary shares, issued on 17 December 2025. The substantial increase in quoted securities expands the company’s share base and may provide additional c...
Skin Elements Issues 125 Million New Shares Following Option Conversions
Dec 24, 2025
Skin Elements Limited has notified the market of the issue of 125 million new fully paid ordinary shares following the exercise or conversion of previously unquoted options or convertible securities. The substantial increase in the company’s...
Skin Elements Issues Shares and Options to Director in Lieu of Fees
Dec 22, 2025
Skin Elements Limited has disclosed a substantial change in the holdings of director Peter Malone, reported as an indirect interest via several trustee and beneficiary structures. The filing details the issue of 400 million new ordinary shares at ...
Skin Elements Issues 37.5 Million Unquoted Options
Dec 19, 2025
Skin Elements Limited has disclosed the issue of 37.5 million unquoted options, exercisable at $0.006 and expiring on 12 December 2028, as part of its latest capital-related corporate actions. The move increases the company’s pool of equity-...
Skin Elements Seeks ASX Quotation for 75 Million New Shares
Dec 19, 2025
Skin Elements Limited has applied to the ASX for quotation of 75 million new ordinary fully paid shares, issued on 18 December 2025 as Lead Manager shares under shareholder approval granted on 28 November 2025. The move will expand the companyR...
Skin Elements Completes Major Share Allotment to Strengthen Market Position
Dec 17, 2025
Skin Elements Limited has completed the allotment of 1,092,500,000 fully paid ordinary shares as part of a two-tranche placement, with an additional 500,000,000 shares allotted to a director and senior executive following shareholder approval. Thi...
Skin Elements Limited Issues 250 Million Unquoted Equity Securities
Dec 15, 2025
Skin Elements Limited announced the issuance of 250 million unquoted equity securities in the form of options exercisable at $0.006, set to expire on December 12, 2028. This strategic move could potentially enhance the company’s capital stru...
Skin Elements Limited to Quote 500 Million New Securities on ASX
Dec 15, 2025
Skin Elements Limited announced the approval and upcoming quotation of 500,000,000 ordinary fully paid securities on the ASX, following shareholder approval received on November 28, 2025. This move is expected to enhance the company’s capita...
Skin Elements Issues Unquoted Equity Securities
Dec 15, 2025
Skin Elements Limited has announced the issuance of 625,000,000 unquoted equity securities, specifically options exercisable at $0.006 and expiring on December 12, 2028. This move is part of a previously announced transaction and is not intended t...
Skin Elements Limited Announces Quotation of New Securities on ASX
Dec 11, 2025
Skin Elements Limited has announced the quotation of 1,092,500,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective December 12, 2025. This move is part of previously announced transactions and is expected to e...
$2.5M Placement Boosts Skin Elements’ ECO Nurture Launch
Dec 11, 2025
Skin Elements Limited has successfully completed a $2.5 million placement to fund the commercialization of its ECO Nurture bio-stimulant, aimed at protecting kiwifruit orchards in New Zealand. This strategic move positions the company to offer a s...
Skin Elements Limited Announces 2025 AGM with Digital Access
Oct 30, 2025
Skin Elements Limited has announced its 2025 Annual General Meeting, scheduled for November 28, 2025, in West Perth, Australia. The company is adapting to the Corporations Amendments Act 2022 by providing electronic access to the Notice of Meeting...
Skin Elements Completes Major Share Allotment
Oct 23, 2025
Skin Elements Limited has completed the allotment of 157,500,000 fully paid ordinary shares as part of a two-tranche placement with 62 Capital Pty Ltd as the lead manager. This move, announced on 15 October 2025, signifies the company’s stra...
Skin Elements Limited Announces Quotation of New Securities
Oct 23, 2025
Skin Elements Limited has announced the quotation of 157,500,000 ordinary fully paid securities on the Australian Securities Exchange. This move is part of previously announced transactions and could potentially enhance the company’s market ...
Skin Elements Limited Announces Proposed Securities Issue
Oct 15, 2025
Skin Elements Limited announced a proposed issue of securities, with plans to issue 37.5 million options exercisable at $0.006 and 75 million fully paid ordinary shares. This move is expected to enhance the company’s capital base, potentiall...
Skin Elements Limited Announces Significant Securities Issuance
Oct 15, 2025
Skin Elements Limited has announced a proposed issuance of securities, including 625,000,000 options and 1,092,500,000 fully paid ordinary shares, with a planned issue date of December 1, 2025. This move is likely to impact the company’s fin...
Skin Elements Limited Announces Proposed Securities Issue
Oct 15, 2025
Skin Elements Limited has announced a proposed issue of 157,500,000 fully paid ordinary securities, scheduled for issuance on October 20, 2025. This move is part of the company’s strategy to raise capital, potentially impacting its market po...
Skin Elements Secures $2.5 Million for SE Formula Commercialization
Oct 15, 2025
Skin Elements Limited has secured $2.5 million through a two-tranche placement at $0.002 per share, with additional options, to fund the commercialization of its SE Formula biotechnology. This capital injection, managed by 62 Capital Pty Ltd, will...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.